Netscientific Share Discussion Threads

[blakieboy7] 04/8/2022 21:55

PDSB RNS - On August 4, 2022, PDS Biotechnology Corporation issued a press release announcing its independent Data Monitoring Committee (DMC) met for its scheduled review of PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the potential treatment of recurrent or metastatic HPV16-positive head and neck cancer. Based on their review of patients with available safety data, the DMC recommended continuing the trial without modifications because PDS0101 in combination with KEYTRUDA® continues to appear safe and well tolerated.

[senttothegallows] 04/8/2022 19:50

Yes don't worry uk will ignore pdsb increase it does everytime utter madness and has to catch on eventually imho

[blakieboy7] 04/8/2022 19:40

PDSB now over 12% up today

[blakieboy7] 04/8/2022 17:45

PDSB up over 7% again so far!

[michelle74] 04/8/2022 13:48

Nothing happens here just all talk

[blakieboy7] 04/8/2022 10:54

Still no movement today after PDSB rise yesterday! Unbelievable

[blakieboy7] 03/8/2022 15:05

I've just noticed PDSB, moving up nicely

[senttothegallows] 03/8/2022 14:49

PDSB ever increasing share price continues to be ignored utter madness IMHO

[loafofbread] 30/7/2022 14:58

ProAxsis announces additional key appointments
JULY 26, 2022-POSTED BY JESSICA ROBINSON
As part of its continuing expansion, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce further key appointments within its Northern Ireland team.

Dr Louise Ryan Murphy joins the company as Head of Business Operations. Louise brings a wealth of operational experience to ProAxsis, having previously held roles at Abbott Diagnostics, Horizon Discovery and PredictImmune with a focus on IVD medical devices. In her new role, she will be responsible for overseeing all in-house product development and clinical services projects as well as product manufacture and quality assurance activities.

Louise Ryan Murphy, newly appointed Head of Business Operations at ProAxsis, added: “I am delighted to be joining ProAxsis at such an exciting period of expansion and growth for the company. I have been very impressed with the in-house talent and what they have achieved to date. I look forward to working with the team as we continue to expand and streamline operations, and to contributing significantly to the future success of the company.”

In addition, the company welcomes three new members of its R&D team – Ashleigh Kennedy, who returns to us after four years having previously completed a placement year at ProAxsis, Niall McDonagh and Matthew McCaffrey. Ashleigh was most recently working at Almac, whilst Niall joins us from Randox. Matthew also previously completed a placement year with the company and re-joins the company from Queen’s University Belfast.

Dr David Ribeiro, CEO of ProAxsis, commented: “We’re thrilled to have enticed someone of Louise’s calibre and experience to relocate back to Northern Ireland and become part of the World-leading diagnostics community here. We’re also delighted to further expand our R&D team via the additions of Ashleigh, Niall and Matthew.”

Due to the growing nature of the company, we continue to look for high-quality candidates to join our team. Any new opportunities will be posted on our website – www.proaxsis.com

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials. ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.

[blakieboy7] 21/7/2022 17:05

PDSB up another 7%

[blakieboy7] 21/7/2022 11:49

I couldn't agree more. We have so many prized assets, even if just one were to rocket!!!

[senttothegallows] 21/7/2022 11:33

When you looking at what is going on in there underlying portfolio current sahre price makes no sense. Patience is always the key with these imho

[blakieboy7] 21/7/2022 10:38

A bit of blue - lots more needed

[blakieboy7] 21/7/2022 09:44

Makes no sense to me gallows!

[senttothegallows] 21/7/2022 08:31

As ever market ignores the 9% rise in pdsb share price madness imho

[blakieboy7] 20/7/2022 22:09

PDSB closed 9% up, hopefully bodes well for tomorrow

[kingston78] 15/7/2022 14:05

A company called Angle was at 150 p not long ago, but has since declined to about 80 p where the company is raising £20 million by way of placing at 80 p each share.

Many companies run out of money. The market is fragile.

Aston Martin, however, has gone up today by 20% to 444 p, maybe due to warmer reception of the subscription of new shares from investors, raising £650 million. But Aston Martin has come down a long long way from its IPO price at 3,500 p.

[longterm3] 05/7/2022 09:23

As a NSCI shareholder you have concluded the quality of the companies investments are excellent and it is sufficiently funded.
That you accept the significant risk inherent in such a company and are satisfied the Market Cap undervalues the portfolio.
In conclusion the wider market has not spotted this tiny companies potential and you are waiting for just one investment to be sold, listed etc - out of a fairly long list.

You are ahead of the herd and in better times will hopefully be feeling vindicated.

[kingston78] 05/7/2022 09:03

Despite what the CEO says that the company is undervalued there is apparently no follow through support. Those who are fully invested will not want to top up. Unless there is interest from more and newer investors the lack of demand means that the share price will not go up until a significant positive announcement. The company's broker and the directors will pitch the company to a wider audience.

[kingston78] 30/6/2022 11:58

It is cheaper to buy now than the placing price if anyone is interested.

[kingston78] 28/6/2022 19:40

Placing is at the discretion of the Nomad / Company. This is the unfortunate consequence of the rules, unlike a general open offer to all shareholders. It so happened that the share price was declining, leading up to the event. In theory, an insider could engineer a lower price by selling down the shares, but that would have been criminal had they been found out. Trading was light anyway. Today, the number of shares traded is miniscule.

[loafofbread] 28/6/2022 18:31

Looks like the recent placing was just a cheap handout to the BOD and their mates.

Assume they see value but what a stitch up.

[kingston78] 23/6/2022 08:41

Terminator101, no one is attacking you. No one works for free unless they are charity volunteers. You seem to be an angry man. Please don't channel your anger to us. Go fishing to calm yourself if you have the patience.

Share prices rise and fall, just like every other commodity. We shall wait and see how this company develops in the next few years.